The Efficacy of Taxane Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation CarriersKRIEGE, Mieke; JAGER, Agnes; SEYNAEVE, Caroline et al.Cancer. 2012, Vol 118, Num 4, pp 899-907, issn 0008-543X, 9 p.Article

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)MAVADDAT, Nasim; BARROWDALE, Daniel; MULLIGAN, Anna Marie et al.Cancer epidemiology, biomarkers & prevention. 2012, Vol 21, Num 1, pp 134-147, issn 1055-9965, 14 p.Article

Hereditary breast cancer growth rates and its impact on screening policyTILANUS-LINTHORST, Madeleine M. A; KRIEGE, Mieke; DE KONING, Harry J et al.European journal of cancer (1990). 2005, Vol 41, Num 11, pp 1610-1617, issn 0959-8049, 8 p.Article

BRCA1- Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening StudyRIJNSBURGER, Adriana J; OBDEIJN, Inge-Marie; PETERSE, Hans et al.Journal of clinical oncology. 2010, Vol 28, Num 36, pp 5265-5273, issn 0732-183X, 9 p.Article

Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predispositionKRIEGE, Mieke; BREKELMANS, Cecile T. M; KLIJN, Jan G. M et al.Cancer. 2006, Vol 106, Num 11, pp 2318-2326, issn 0008-543X, 9 p.Article

The Risk of Primary and Contralateral Breast Cancer After Ovarian Cancer in BRCA1/BRCA2 Mutation Carriers: Implications for CounselingVENCKEN, Peggy M. L. H; KRIEGE, Mieke; SEYNAEVE, Caroline et al.Cancer. 2013, Vol 119, Num 5, pp 955-962, issn 0008-543X, 8 p.Article

Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1-and BRCA2-associated compared to sporadic breast cancer patientsKRIEGE, Mieke; SEYNAEVE, Caroline; KLIJN, Jan G. M et al.Breast cancer research and treatment. 2008, Vol 111, Num 2, pp 303-311, issn 0167-6806, 9 p.Article

The role of genetic breast cancer susceptibility variants as prognostic factorsFASCHING, Peter A; PHAROAH, Paul D. P; DUNNING, Alison M et al.Human molecular genetics (Print). 2012, Vol 21, Num 17, pp 3926-3939, issn 0964-6906, 14 p.Article

Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation CarriersSPURDLE, Amanda B; MARQUART, Louise; GSCHWANTLER-KAULICH, Daphne et al.Cancer epidemiology, biomarkers & prevention. 2011, Vol 20, Num 5, pp 1032-1038, issn 1055-9965, 7 p.Article

Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation CarriersKRIEGE, Mieke; SEYNAEVE, Caroline; VAN DEN OUWELAND, Ans et al.Journal of clinical oncology. 2009, Vol 27, Num 23, pp 3764-3771, issn 0732-183X, 8 p.Article

CHEK2^*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer―Specific Death, and Increased Risk of a Second Breast CancerWEISCHER, Maren; NORDESTGAARD, Børge G; DEVILEE, Peter et al.Journal of clinical oncology. 2012, Vol 30, Num 35, pp 4308-4316, issn 0732-183X, 9 p.Article

Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancerKRIEGE, Mieke; BREKELMANS, Cecile T. M; TILANUS-LINTHORST, Madeleine M. A et al.Breast cancer research and treatment. 2006, Vol 100, Num 1, pp 109-119, issn 0167-6806, 11 p.Article

Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predispositionKRIEGE, Mieke; BREKELMANS, Cecile T. M; MULLER, Sara H et al.The New England journal of medicine. 2004, Vol 351, Num 5, pp 427-437, issn 0028-4793, 11 p.Article